Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

4.90GBp
23 May 2017
Change (% chg)

0.02 (+0.41%)
Prev Close
4.88
Open
4.91
Day's High
5.33
Day's Low
4.89
Volume
2,389,913
Avg. Vol
4,495,422
52-wk High
6.00
52-wk Low
2.98

Latest Key Developments (Source: Significant Developments)

Oxford Biomedica notes acceptance by FDA of a biologics license application filing for CTL019
Thursday, 30 Mar 2017 02:02am EDT 

Oxford Biomedica Plc : Oxford Biomedica notes acceptance by FDA of a biologics license application (BLA) filing for CTL019 .Oxford Biomedica will also receive undisclosed royalties on potential future sales of Novartis Car-T products..  Full Article

Oxford biomedica says FY EBITDA loss reduced to £7.1 mln
Thursday, 16 Mar 2017 03:13am EDT 

Oxford Biomedica Plc : Fy EBITDA loss reduced to £7.1 million .Fy gross income increased by 64% to £30.8 million.  Full Article

Oxford biomedica says Trovax shown to induce beneficial anti-tumour immune responses
Friday, 24 Feb 2017 02:28am EST 

Oxford Biomedica Plc : Cyclophosphamide and Trovax independently shown to induce highly beneficial anti-tumour immune responses .Both drugs resulting in significantly prolonged survival of advanced colorectal cancer patients.  Full Article

Oxford Biomedica says Chief Development Officer Blake to leave in Aug
Thursday, 12 May 2016 02:11am EDT 

Oxford Biomedica Plc : Announces that Dr Paul Blake will leave group when his current contract expires at end of August 2016. .Blake was appointed to Oxford Biomedica's board as a non-executive director in January 2010 and subsequently he became chief development officer in September 2014..  Full Article

More From Around the Web

BRIEF-Oxford Biomedica notes acceptance by FDA of a biologics license application filing for CTL019

* Oxford Biomedica notes acceptance by FDA of a biologics license application (BLA) filing for CTL019